STAR 0603
Alternative Names: STAR-0603Latest Information Update: 27 Feb 2024
At a glance
- Originator Marengo Therapeutics
- Class Antibodies; Antineoplastics; Recombinant fusion proteins
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 22 Feb 2024 Early research in Solid tumours in USA (Parenteral), before February 2024 (Marengo Therapeutics pipeline, February 2024)